HARP News and Press, Harpoon Therapeutics Inc. From 05/11/23

Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical posters presented at AACR 2023 in April on HPN217, HPN328 and ProTriTAC™ development ca...

2023-04-21 17:55:32 ET Harpoon Therapeutics ( NASDAQ: HARP ) has filed for a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital and general...

Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor activity γ-secretase inhibitors increased the potency of HPN217 in vitro in multiple c...

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data on two new development candidates from the proprietary ProTriTAC™ ...

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Of...

2023-03-27 17:13:08 ET Harpoon Therapeutics press release ( NASDAQ: HARP ): Q4 GAAP EPS of -$0.55 misses by $0.08 . Revenue of $4.1M (-5.3% Y/Y) misses by $2.94M . Shares -4.26% AH. For further details see: Harpoon Therapeutics GAAP EPS of -$0.55 ...

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred equity financing provides sufficient cash to fund operations into the second half o...

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred s...

Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC ® ) platform and support ongoing clinical efforts Additional abstrac...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this event. For further details see: Harpoon Therapeutics (HARP) Presents at SVB Securities Global Biopharma Conference 2023